SCHAUMBURG, Ill., Nov 05, 2010 (BUSINESS WIRE) --
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it will launch the APP Drug Hotline on Wednesday, November 10, 2010. The APP Drug Hotline has been established to assist healthcare professionals with critical drug shortage issues.
Staffed by an experienced Customer Service team, the APP Drug Hotline is dedicated to responding to inquires from healthcare professionals seeking information on whether APP's product portfolio can augment the supply of specific drugs currently on the U.S. Food and Drug Administration (FDA) and American Society of Health-System Pharmacists (ASHP) drug shortage lists. APP Drug Hotline staff will provide callers with an enhanced customer service experience, which includes real-time information on APP's available supply of specific drugs currently on drug shortage, details on upcoming APP product releases, as well as help callers track their APP orders.
"Throughout the years, APP Pharmaceuticals has demonstrated that it can meet the challenges of critical drug shortages, and we are acutely aware of the pressure that healthcare professionals are under when a needed drug is unavailable. We have worked collaboratively with the FDA to alleviate shortages for many products ranging from acyclovir to heparin and most recently propofol," said John Ducker, President and CEO, APP Pharmaceuticals. "Responsiveness is APP's commitment to healthcare professionals and we understand the importance of product supply meeting patient demand."
Healthcare professionals looking to learn more about how APP can help with their drug shortage needs can reach the APP Drug Hotline at (888) 386-1300, option 6. The APP Drug Hotline is available Monday through Friday, between the hours of 7:00 a.m. and 6:00 p.m. (CST).
Information on current inventory and product availability is also accessible on the company's Web site, www.APPpharma.com, by clicking on Drug Shortage Solutions.
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company's Web site at www.apppharma.com.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy "caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million and an operating profit of EUR 607 million. For more information visit the company's Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. Additional relevant information concerning risks are discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2009 and other documents the company has filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.
SOURCE: APP Pharmaceuticals, Inc.
APP Media and Investor Relations
APP Pharmaceuticals, Inc.
Debra Lynn Ross, ABC
Director, Corporate Communications